The difference in the cellular response of both breast cancer cell lines can be explained by the expression of HER2 receptors on MCF-7 cell lines, which are mostly treated with aromatase inhibitors (Trozole) and Tamoxifen, an antagonist of ER [42]. Here, CYP19A1 is linked to breast carcinoma.